The role of ADME evaluation in translation research of innovative drug

Yaoxue Xuebao

Volumn 46, Issue 1, 2011, Pages 19-29

  Liu, Yao ^a   Hong, Lan ^a   Yu, Lu Shan ^a   Jiang, Hui Di ^a   Chen, Jian Zhong ^a   Meng, Qin ^b   Chen, Shu Qing ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Drug disposition; Drug likeness; New drug research and development; Translation research

Indexed keywords

CLINICAL EVALUATION; COST; DRUG ABSORPTION; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; REVIEW;

ABSORPTION; BIOLOGICAL TRANSPORT; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79551486135     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Critical Path Reports [EB/OL]. US FDA: Silver Spring, MD. [2010-09-10]. http://www.fda.gov/ScienceResearch/Special-Topics/CriticalPathInitiative/ CriticalPathOpportunitiesReports.
2. Hodgson J. ADMET - turning chemicals into drugs [J]. Nat Biotechnol, 2001, 19: 722-726.
3. Selick HE, Beresford AP, Tarbit MH. The emerging importance of predictive ADME simulation in drug discovery [J]. Drug Discov Today, 2002, 7: 109-116.
4. Baranczewski P, Stanczak A, Sundberg K, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development [J]. Pharmacol Rep, 2006, 58: 453-472. (Pubitemid 44383272)
5. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? [J]. Nat Rev Drug Discov, 2004, 3: 711-715.
6. A JY, Wang GJ. Drug metabolism research for the design and structural modification of drugs [J]. Prog Pharm Sci, 2002, 26: 80-86.
7. Zhao DM, Li Y, Lu YH. The role of drug metabolism in new drug development [J]. Acta Pharm Sin, 2000, 35: 156-160.
8. Zeng S. Enhancing study on drug metabolism in pharmaceutical sciences [J]. J Zhejiang Univ (Med Sci), 2008, 37: 109-112.
9. Guo ZR. Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule [J]. Acta Pharm Sin, 2008, 43: 227-233.
10. Alter SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding [J]. Science, 2009, 323: 1718-1722.
11. Williams PA, Cosme J, Vinkovic DM, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone [J]. Science, 2004, 305: 683-686. (Pubitemid 39006760)
12. Williams PA, Cosme J, Ward A, et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin [J]. Nature, 2003, 424: 464-468. (Pubitemid 36917499)
13. Miley MJ, Zielinska AK, Keenan JE, et al. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7 [J]. J Mol Biol, 2007, 369: 498-511.
14. Locuson CW, Gannett PM, Ayscue R, et al. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9 [J]. J Med Chem, 2007, 50: 1158-1165. (Pubitemid 46496316)
15. de Graaf C, Oostenbrink C, Keizers PH, et al. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6 [J]. Curr Drug Metab, 2007, 8: 59-77. (Pubitemid 46043892)
16. Ahlström MM, Ridderström M, Zamora I. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites [J]. J Med Chem, 2007, 50: 5382-5391.
17. Klepsch F, Ecker GF. Impact of the recent mouse P-glycoprotein structure for structure-based ligand design [J]. Mol Inform, 2010, 29: 276-286.
18. Sun H, Scott DO. Structure-based drug metabolism predictions for drug design [J]. Chem Biol Drug Des, 2010, 75: 3-17.
19. He L, He F, Bi HC, et al. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations [J]. Bioorg Med Chem Lett, 2010, 20: 6008-6012.
20. Bazeley PS, Prithivi S, Struble CA, et al. Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: Predicting affinity and conformational sampling [J]. J Chem Inf Model, 2006, 46: 2698-2708. (Pubitemid 46008139)
21. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J]. Pharmacogenomics J, 2005, 5: 6-13. (Pubitemid 40220611)
22. Eaton DL, Gallagher EP. Mechanisms of aflatoxin carcinogenesis [J]. Annu Rev Pharmacol Toxicol, 1994, 34: 135-172.
23. Mulholland AJ. Modelling enzyme reaction mechanisms, specificity and catalysis [J]. Drug Discov Today, 2005, 10: 1393-1402. (Pubitemid 41501794)
24. Shaik S, Cohen S, Wang Y, et al. P450 Enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations [J]. Chem Rev, 2010, 110: 949-1017.
25. Ekins S, Drug transporter pharmacophores[M]//Ecker GF, Chiba P. Transporters as Drug Carriers: Structure, Function, Substrates. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2009: 215-227.
26. Penzotti JE, Lamb ML, Evensen E, et al. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein [J]. J Med Chem, 2002, 45: 1737-1740.
27. Chang C, Ekins S. Pharmacophores for human ADME/Tox-related proteins, in pharmacophores and pharmacophore searches [M]. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2006: 299-324.
28. Schuster D, Laggner C, Steindl TM, et al. Development and validation of an in silico P450 profiler based on pharmacophore models [J]. Curr Drug Discov Technol, 2006, 3: 1-48.
29. Crivori P, Reinach B, Pezzetta D, et al. Computational models for identifying potential P-glycoprotein substrates and inhibitors [J]. Mol Pharm, 2006, 3: 33-44.
30. Byvatov E, Baringhaus KH, Schneider G, et al. A virtual screening filter for identification of cytochrome P450 2C9 (CYP2C9) inhibitors, in QSAR & Combinatorial Science [M]. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2007.
31. Freitas RF, Bauab RL, Montanari CA. Novel application of 2D and 3D-similarity searches to identify substrates among cytochrome P450 2C9, 2D6, and 3A4 [J]. J Chem Inf Model, 2010, 50: 97-109.
32. Vedani A, Dobler M, Lill MA. The challenge of predicting drug toxicity in silico [J]. Basic Clin Pharmacol Toxicol, 2006, 99: 195-208.
33. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb [J]. J Med Chem, 2008, 51: 817-834.
34. Chohan KK, Paine SW, Waters NJ. Quantitative structure activity relationships in drug metabolism [J]. Curr Top Med Chem, 2006, 6: 1569-1578.
35. Pajeva IK, Globisch C, Wiese M. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCCl transporter inhibitors [J]. ChemMedChem, 2009, 4: 1883-1896.
36. Korhonen LE, Turpeinen M, Rahnasto M, et al. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis [J]. Br J Pharmacol, 2007, 150: 932-942.
37. Pick A, Muller H, Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2) [J]. Bioorg Med Chem, 2008, 16: 8224-8236.
38. Chohan KK, Paine SW, Waters NJ. Advancements in predictive in silico models for ADME [J]. Curr Chem Biol, 2008, 2: 215-228.
39. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters [J]. J Pharmacol Exp Ther, 2004, 311: 315-323.
40. Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin [J]. J Clin Pharmacol, 2008, 48: 1378-1388.
41. Dobson PD, Patel Y, Kell DB. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries [J]. Drug Discov Today, 2009, 14: 31-40.
42. Zeng S. Drug Metabolism [M]. Hangzhou: Zhejiang University Press, 2008.
43. Guidance for Industry: nonclinical pharmacokinetics of chemical drug, [H]GPT5-1[EB/OL]. SFDA. 2004 [2010-09-10]. http://www.sfda.gov.cn/WS01/CL0001/.
44. Hu XY, Yao TW, Zeng S. Application of Caco-2 cells to drug absorption and metabolism [J]. Chin J Mod App Pharm, 2002, 19: 88-90.
45. Wang XD, Zeng S. Advances in Caco-2 cells and drug absorption [M]//Wei MJ. Methods for Studying ADME of New Drugs. Beijing: China Medical Science and Technology Press, 2007.
46. Yu L, Zeng S. Transport characteristics of zolmitriptan in a human intestinal epithelial cell line Caco-2 [J]. J Pharm Pharmacol, 2007, 59: 655-660. (Pubitemid 47051108)
47. Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. US FDA: Silver Spring, MD, 2006 [2010-09-10]. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4079B1- 04-Topic2-TabA.pdf.
48. Liu Y, Yu CN, Zeng S. Establishment of MDCK cell line with high p-glycoprotein expression [J]. Chin Pharm J, 2009, 44: 1608-1613.
49. Liu Y, Wang XD, Yu CN, et al. BYYTs permeability across an in vitro model of the blood-brain barrier [J]. Drug Metab Rev, 2008, 40: 209.
50. Liu Y, Zeng S. Advances in the MDCK-MDR1 cell model and its applications to screen drug permeability [J]. Acta Pharm Sin, 2008, 43: 559-564.
51. Wang Y, Cao J, Zeng S. Establishment of a P-glycoprotein substrate screening model and its preliminary application [J]. World J Gastroenterol, 2004, 10: 1365-1368. (Pubitemid 39162450)
52. Wang Y, Cao J, Zeng S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin [J]. J Pharm Pharmacol, 2005, 57: 751-758.
53. Wang Y, Cao J, Weng JH, et al. Simultaneous determination of quercetin, kaempferol and isorhamnetin accumulated human breast cancer cells, by high-performance liquid chromatography [J]. J Pharm Biomed Anal, 2005, 39: 328-333.
54. -) sulfonate sodium across Caco-2 cell monolayers [J]. J Pharm Pharmacol, 2005, 57: 1297-1303.
55. Wang XJ, Jin YX, Ying JY, et al. Determination of rutin deca(H-) sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2006, 833: 231-235.
56. Wang FM, Yao TW, Zeng S. Disposition of quercetin and kaempferol in human following an oral administration of Ginkgo biloba extract tablets [J]. Eur J Drug Metab Pharmacokinet, 2003, 28: 173-177. (Pubitemid 37163061)
57. DuPont MS, Day AJ, Bennett RN, et al. Absorption of kaempferol from endive, a source of kaempferol-3-glucuronide, in humans [J]. Eur J Clin Nutr, 2004, 58: 947-954.
58. Wang XD, Meng MX, Gao LB, et al. Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp [J]. Int J Pharm, 2009, 378: 1-8.
59. Wang X, Xia H, Xing F, et al. A highly sensitive and robust UPLC-MS with electrospray ionization method for quantitation of taxifolin in rat plasma [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2009, 877: 1778-1786.
60. Comparison of Postapproval Risks for Drugs Approved Before and After the Implementation of PDUFA [EB/OL]. US FDA: Silver Spring, MD, 2009 [2010-09-10]. http://www.fda.gov/Safety/SafetyofSpecificProducts/ucm180599.htm.
61. Risk Intervention Examples [EB/OL]. US FDA: Silver Spring, MD, 2009 [2010-09-10]. http://www.fda.gov/Safety/SafetyofSpecificProducts/ucm180605.htm.
62. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical [J]. AAPS J, 2008, 10: 391-400.
63. Xie W, Evans RM. Pharmaceutical use of mouse models humanized for the xenobiotic receptor [J]. Drug Discov Today, 2002, 7: 509-515. (Pubitemid 34450938)
64. Yu C, Ye S, Sun H, et al. PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA [J]. Chem Biol Interact, 2009, 177: 58-64.
65. Yu L, Lu S, Lin Y, et al. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases [J]. Biochem Pharmacol, 2007, 73: 1842-1851.
66. Wang XW, Zeng S. Heterogenous expression and activity analysis of human cytochrome P450 3A4 mutants CYP3A4.3, CYP3A4.4, CYP3A4.5 and CYP3A4.18 [J]. Chin J Pharmacol Toxicol, 2009, 23: 456-463.
67. Ruan H, Chen SQ, Yao TW. Heterogenous expression and activity determination of human cytochrome P450 1A2 [J]. Chin J Modern App Pharm, 2009, 26: 697-702.
68. Lu K, Zeng S, Yao TW. Expression of human CYP2E1 in insect cells using bac-to-bac expression system [J]. Zhejiang Univ (Med Sci), 2008, 37: 118-125.
69. Lv Q, Chen SQ, Zeng S. Study heterogenous expression and activity determination of human cytochrome P450 2B6 [J]. Chin Pharm J, 2007, 42: 1610-1614. (Pubitemid 350189250)
70. Zheng SL, Qian MR, Li X, et al. Expression of human UGT1A6 in insect cell with baculovirus expression system [JJ. Chin J Pharmacol Toxicol, 2004, 18: 444-448. (Pubitemid 40292349)
71. Gao LB, Wang JZ, Zeng S. Cloning, expression and the application of human, rat alcohol dehydrogenase and aldo-keto reductase [J]. Acta Pharm Sin, 2009, 44: 778-784.
72. Zhou Q, Yao TW, Zeng S. Chiral reversed phase high-performance liquid chromatography for determining propranolol enantiomers in transgenic Chinese hamster CHL cell lines expressing human cytochrome P450 [J]. J Biochem Biophys Methods, 2002, 54: 369-376.
73. Zhang X, Yao Y, Lou Y, et al. Metabolism of ebracteolata compound B studied in vitro with human liver microsomes, HepG2 cells, and recombinant human enzymes [J]. Drug Metab Dispos, 2010, 38: 2157-2165.
74. Yu L, Qian M, Liu Y, et al. Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9 [J]. Chirality, 2010, 22: 456-461.
75. Luan LJ, Shao Q, Ma JY, et al. Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects [J]. World J Gastroenterol, 2005, 11: 1822-1824. (Pubitemid 40520777)
76. Qian M, Chen S, Li X, et al. Cloning and expression of human UDP-glucuronosyltransferase 1A4 in Bac-to-Bac system [J]. Biochem Biophys Res Commun, 2004, 319: 386-392.
77. Qian MR, Zeng S. Biosynthesis of Imipramine glucuronide and characterization of Imipramine glucuronidation catalyzed by recombinant UGT1A4 [J]. Acta Pharmacol Sin, 2006, 27: 623-628.
78. Chen Y, Xie S, Chen S, et al. Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9 [J]. Biochem Pharmacol, 2008, 76: 416-425.
79. Grossman I. ADME pharmacogenetics: current practices and future outlook [J]. Expert Opin Drug Metab Toxicol, 2009, 5: 449-462.
80. Katz DA, Murray B, Bhathena A, et al. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy [J]. Nat Rev Drug Discov, 2008, 7: 293-305.
81. Williams JA, Andersson T, Andersson TB, et al. PhRMA white paper on ADME pharmacogenomics [J]. J Clin Pharmacol, 2008, 48: 849-889.
82. Tu JH, Hu DL, Dai LL, et al. Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes [J]. Xenobiotica, 2010, 40: 393-399.
83. Table of valid genomic biomarkers in the context of approved drug labels [EB/OL]. US FDA: Silver Spring, MD, 2009 [2010-09-10]. http://www.fda.gov/cder/ genomics/genomic-biomarkers-table.htm.
84. Guidance for industry: pharmacogenomic data submissions [EB/OL]. US FDA: Silver Spring, MD, 2005 [2010-09-10]. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM126957.pdf.
85. Yuan LM, Chen J, Zeng S. Construction, expression and activities of three active variants of human uridine diphosphate glucuronic acid transferase 2B7 [J]. Chin J Pharmacol Toxicol, 2008, 22: 274-281.
86. Chen Y, Chen S, Li X, et al. Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population [J]. Drug Metab Dispos, 2006, 34: 1462-1467. (Pubitemid 44285386)
87. Chen YK, Chen SQ, Li X, et al. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters [J]. Xenobiotica, 2005, 35: 943-954. (Pubitemid 43068040)
88. Liu ZH, Zeng S. Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes [J]. Toxicol Lett, 2009, 187: 131-136.
89. Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity [J]. Expert Opin Drug Metab Toxicol, 2010, 6: 733-746.
90. Shen C, Zhang GL, Meng Q. An in vitro model for long-term hepatotoxicity testing utilizing rat hepatocytes entrapped in micro-hollow fiber reactor [J]. Biochem Eng J, 2007, 34: 267-272. (Pubitemid 46483183)
91. Guidance for Industry: Study on Clinic Pharmacokinetics. SFDA. 2005 [2010-09-10]. http://www.sfda.gov.cn/WS01/CL0001/.
92. Zeng S. Clinic Pharmacokinetics [M]. Beijing: People's Medical Publishing House. 2007.
93. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies [EB/OL]. US FDA: Silver Spring, MD, 2002 [2010-09-10]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070241.pdf.
94. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing and Labeling [EB/OL]. US FDA: Silver Spring, MD, 2010 [2010-09-10]. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf.
95. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling [EB/OL]. US FDA: Silver Spring, MD, 2003 [2010-09-10]. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
96. Guidance for Industry: Pharmacokinetics in Pregnancy - Study Design, Data Analysis, and Impact on Dosing and Labeling [EB/OL]. US FDA: Silver Spring, MD, 2004 [2010-09-10]. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072133.pdf.
97. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products [EB/OL]. US FDA: Silver Spring, MD, 1998 [2010-09-10]. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf.
98. Guidance for Industry: Pharmacogenomic Data Submissions-Companion Guidance [EB/OL]. US FDA: Silver Spring, MD, 2007 [2010-09-10]. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM079855.pdf
99. Guidance for Industry: E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories [EB/OL]. US FDA: Silver Spring, MD, 2008 [2010-09-10]. www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm073162.pdf.